New Evidence-Based Guideline on HER2 Testing for Patients with Gastric Cancer

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

Trodelvy (sacituzumab govitecan-hziy) was added to the NCCN Guidelines as a category 1 preferred first-line treatment option for people with metastatic triple-negative breast cancer whose disease is PD-L1 negative (CPS <10) and no germline BRCA1/2 PV.

January 30, 2026

Vol.52 No.04

Clinical Roundup

ASCO publishes guideline on treating pregnant women with blood cancers

A guideline from the American Society of Clinical Oncology offers clear, evidence-based direction for treating blood cancers during pregnancy and shows that many patients can safely receive timely cancer care without compromising fetal health.

December 19, 2025

Vol.51 No.46

In Brief

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

Nadeem R. Abu-Rustum, Louis Burt Nabors, Michael J. Styler, and James Thompson were recognized by the National Comprehensive Cancer Network as its 2025 awardees who “go above and beyond to define and advance quality, effective, equitable, and accessible cancer care and prevention so all people can live better lives.”xxx:moreAbu-Rustum and Burt Nabors were named recipients of the Excellence in Engagement Awards for 2025—honoring participants from NCCN Clinical Pr

May 30, 2025

Vol.51 No.21

Guest Editorial

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

The U.S. Food and Drug Administration and the U.S. Department of Health and Human Services Office of Human Research Protections issued Draft Guidance on the inclusion of tissue biopsies in clinical trials.

January 17, 2025

Vol.51 No.02

By Laura A. Levit, Mark J. Ratain, Julie R. Gralow, Clifford A. Hudis and Elizabeth Garrett-Mayer

Clinical

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

The National Comprehensive Cancer Network published its first patient resource aimed at informing people about the latest recommendations around hereditary and familial cancer risk. The document provides guidance on testing for inherited genetic mutations that can raise the risk of cancer.

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

The National Comprehensive Cancer Network included circulating tumor DNA testing in their Clinical Practice Guidelines in Oncology for diffuse large B-cell lymphoma. This marks the first-ever inclusion of ctDNA-MRD testing in these guidelines, representing a significant advancement in lymphoma patient care.

January 17, 2025

Vol.51 No.02

New Evidence-Based Guideline on HER2 Testing for Patients with Gastric Cancer

YOU MAY BE INTERESTED IN

Trodelvy added to NCCN guidelines as preferred regimen option for first-line metastatic TNBC

ASCO publishes guideline on treating pregnant women with blood cancers

Abu-Rustum, Burt Nabors, Styler, Thompson receive 2025 NCCN awards

FDA and OHRP draft guidance aims to improve ethics of tissue biopsies in clinical trials

NCCN publishes patient resource on genetic testing to guide patient decisionmaking

NCCN guidelines updated to include ctDNA-MRD testing recommendation for B-cell lymphoma

Renew today!

Subscriber content

Never miss an issue!

Login